The ₹87.6 Crore Growth Story That Isn't—Organic Anlon Is Flat
Consolidated revenue jumped 163%, but 66% came from acquisitions; standalone Anlon fell flat year-over-year. More striking: EBITDA margin collapsed to 17.8% from 30–33% guidance, and management's confidence in a price-pass-through recovery is contradicted by the actual quarter.
The growth mirage
₹87.6 Cr
+163% YoY
₹57 Cr
Apiqo ₹45 Cr + Bizotic ₹12 Cr
₹32 Cr
−3% YoY vs ₹33 Cr prior year
17.8%
vs 30–33% prior guidance (1200 bps miss)
Anlon's headline revenue number is an M&A illusion. Strip out the acquisitions and the core business—the 400 MT API manufacturing operation that defines the franchise—is literally flat year-over-year: ₹32 crore in Q1 FY27 versus ₹33 crore in Q1 FY26, a −3% organic decline. The consolidated ₹87.6 crore sit atop three properties: Apiqo Organics (backward-integrated solvents and fine chemicals, ₹45 crore) acquired at 68% stake and ramping fast; Bizotic Lifesciences (contract manufacturing at existing facilities, ₹12 crore) at 57% stake; and core Anlon at ₹32 crore, capped by its 400 MT installed capacity. The company is already at full-utilization limits on its core asset and growing by bolting on other businesses.
Where the margin crater came from
The culprit is raw material cost inflation. Methanol—a key solvent in API production—more than doubled, from ₹22 per unit to ₹58 over the period; that's 164% cost shock. This represents roughly 40% of API manufacturing costs. On the call, management claimed that price hikes are already underway with customers and that full recovery would show by Q2–Q3. The Q1 results tell a different story: despite knowing about the cost inflation, the company was unable to pass it through in the quarter, which is why EBITDA margin fell 1200 basis points below guidance.
We are already able to increase our cost of the finished product and we have convinced our customer to pay for it. So it will be, I think, reflected in the next one or two quarters.
This is the central claim to watch. Anlon's B2B customer base (10–15 key accounts) has substantial pricing power; receivables are running at 130–135 days versus contractual terms of 90 days, a sign that customers are already pushing back on payment speed. Management framed the pass-through as inevitable, yet Q1 proved it is neither automatic nor immediate. The 'domino effect' management conceded—where cost hikes and price hikes offset each other in percentage terms, leaving margin flat—is the real risk.
Management claims vs. reality
EBITDA margin normalized; expect 25–30% recovery by Q2–Q3
Q1 at 17.8%; revised full-year guidance is 25–27%, not 30%. Normalization pushed to Q2 but unproven.
Overstated
Raw material price increases reflected; pass-through underway
Methanol up 164% but price pass-through did not materialize in Q1. Margin fell 1200 bps, contradicting pass-through claims.
Contradicted
FY27 revenue ₹350–400 Cr guidance maintained
Range is identical to prior calls (370–380 Cr implied). Achieved, but now acquisition-heavy (Anlon core ₹32 Cr, soft)
Supported, but composition shifted
Capacity utilization 65–70%; peak revenue potential ₹350–400 Cr at full utilization
Only ₹87.6 Cr consolidated from 1400–1600 MT suggests lower utilization or softer underlying demand
Overstated / inconsistent
What changed on this call
1. EBITDA margin guidance formally cut. Prior calls had guided 30–33%; now it's 25–27% for FY27 and 25–28% long-term. This is a major downgrade, not a refinement. Management blamed raw material inflation and Remember India integration drag (₹1.29 crore depreciation in Q1, with no revenue yet).
2. Revenue mix shifted to acquisitions. FY27 guidance ₹350–400 Cr was not changed, but the composition is now: core Anlon ₹180 Cr (annualized), Apiqo ₹120–150 Cr, Bizotic ₹60 Cr, Remember India ₹0 (not included). Core Anlon is capped by capacity, so all growth is M&A-driven.
3. Remember India deferred to Q4 FY27. This ₹63.98% acquisition (finished formulations, acquired May 2026) was explicitly excluded from FY27 revenue guidance. WHO-PQ approval expected by year-end; revenue not expected until Q4 at earliest. This is a slide from earlier optimism.
4. Capex increased to ₹130 Cr, now debt-financed. For the new 1200 MT capacity at Anlon standalone: ₹70 Cr from debt (at 8.5–8.6%), ₹60 Cr internal. Q1 FY28 commissioning target; execution contingent on statutory approvals. Any delay ripples through the ₹700 crore FY28 target.
Consolidated revenue growing (+163% YoY, driven by Apiqo + Bizotic)
Organic Anlon flat year-over-year (₹32 Cr vs ₹33 Cr); capacity-capped
Apiqo fully booked/overbooked; backward integration de-risks solvent costs
EBITDA margin guidance missed by 1200 bps (30–33% → 17.8% actual); cut to 25–27% for FY27
Price pass-through claimed but not delivered in Q1; customer concentration limits pricing
₹130 Cr capex for 1200 MT capacity with ₹700 Cr FY28 target (if executed)
Remember India not expected to contribute revenue until Q4 FY27; integration drag ongoing
Seven new API DMF filings on track; CDMO molecules in commercial supply by Q3–Q4
Risks, ranked by impact on holders
Raw material pass-through fails to materialize; B2B customer pricing power holds
HighQ1 margin miss proved that cost inflation doesn't automatically translate to price increases. If customers refuse higher prices (they have 10–15 account concentration + 130–135 day payables = negotiating leverage), EBITDA margin stays at 17–20% instead of recovering to 25–27%.
Remember India delays; WHO-PQ approval misses year-end target or ramp is slower
HighCurrently a depreciation drag (₹1.29 Cr in Q1) with no revenue. FY28 margin uplift assumes formulations (target >25% margin) contribute meaningfully. Any delay pushes upside to FY28 Q2+ and increases integration risk.
Capex execution slips; 1200 MT capacity misses Q1 FY28 target
High₹700 crore FY28 target depends on new capacity at 50–60% utilization by Q1. Management acknowledged 1–2 month delays are possible; those delays immediately cascade into full-year guidance.
Customer concentration and receivables; working capital stress or credit loss
Medium-HighB2B base of 10–15 accounts paying 130–135 days (vs 90-day terms) suggests cash-flow tightness or customer credit stress. A single large customer default or slowdown would hit cash flow disproportionately.
Organic Anlon stagnation continues; M&A only outlet for growth
MediumCore business flat YoY suggests either market saturation or weak demand. If acquisition opportunities dry up after Apiqo/Bizotic/Remember India, consolidated growth rates will be much lower than the guided 30% CAGR.
Standalone Anlon capacity under-utilized vs. claims; soft underlying demand
MediumManagement claims 65–70% utilization with ₹350–400 Cr peak potential, but only ₹87.6 Cr consolidated suggests either lower utilization or lower peak potential. If demand is softer, new capacity may not hit 50–60% utilization either.
How the street is positioned
The stock has cratered from an all-time high of ₹172.75 to ₹14.43, a −91.65% drawdown. This is the kind of collapse that typically reflects either fraud, a structural business breakdown, or severe overvaluation at the peak. Here, the latter—the stock was hyped on the 30% CAGR promise and multiple acquisition announcements, then reality (margin miss, organic stagnation, Remember India delays) set in.
The post-result price action is telling: a day-1 pop of +0.62% (minimal conviction) that faded to −2.13% by day 5. The market saw through the headline revenue number and wasn't reassured by the call. RSI at 29.9 signals oversold conditions, which can attract bottom-fishers, but institutional selling persists: DIIs trimmed from 4.60% to 1.22% (−3.38 percentage points), while FIIs nibbled up from 0.32% to 1.67% (+1.35 pp). The DII exit is the warning sign—domestic institutions are exiting, not averaging down. Bulk deals show Neomile Growth Fund-Series I selling 1.01 crore shares @ ₹14.31 and 0.21 crore @ ₹16.31, suggesting PE/growth capital is cutting exposure in the mid-₹14–₹16 range.
What to watch next
1 · Q2 EBITDA margin
Management claims Q2 will show improvement as price hikes take hold. If Q2 margin stays below 22% or shows no uplift, the pass-through thesis fails and guidance is at risk. This is the credibility test.
2 · Remember India WHO-PQ approval
Expected by year-end (Dec 2026). Delays here push revenue ramp to FY28 Q2 and increase integration drag. Approval on time unlocks Q4 ramp narrative.
3 · New capacity commissioning progress
₹130 Cr capex for 1200 MT Anlon facility targeting Q1 FY28. Any slip in statutory approvals or construction timelines should emerge in Q2 guidance update. This drives the ₹700 Cr FY28 scenario.
Anlon is a company in transition: divesting from a stagnant core business (organic Anlon is flat) into acquisitions (Apiqo, Bizotic, Remember India) and new capacity to chase a 30% CAGR and ₹700 crore FY28 target. That strategy is coherent if executed, but Q1 reveals management's execution credibility is dented. A 43% miss on EBITDA guidance and a price pass-through that didn't materialize in the quarter are red flags. The stock has fallen 92% from its peak and is oversold, but the post-result bounce faded within days—the street is unconvinced.
The number to track is Q2 EBITDA margin. If it rises above 22% and trends toward the 25–27% FY27 guidance, the pass-through thesis holds and the debate tilts bullish. If it stays below 20%, the bear case wins and guidance will crack further. Until then, this is a reduce / hold on execution risk and weakened credibility, despite technical oversold conditions.
Anlon Healthcare Q1 FY27: consolidated PAT ₹8.28 Cr, +134% YoY, margins dilute
PAT +133.5% YoY · revenue +163% · margins compressing
₹87.56 Cr
+163% YoY
₹8.28 Cr
+133.5% YoY
9.45%
₹0.16
On a consolidated basis (primary), Anlon Healthcare posted PAT of ₹8.28 Cr, up 134% YoY but down 25% QoQ, on revenue of ₹87.56 Cr, up 163% YoY and 72% QoQ. Nearly all of that growth is the first full-quarter consolidation of Apiqo Organics and Bizotic Lifescience (combined ₹57.07 Cr revenue, ₹3.48 Cr PAT per the auditor's note), not organic acceleration — the standalone (core API) business actually shows revenue of ₹30.98 Cr, down 7.0% YoY and 44.1% QoQ (Q4 FY26 was seasonally elevated at ₹55.42 Cr), with standalone PAT of ₹4.80 Cr up 35.3% YoY on margin expansion (NPM 15.5% vs 10.7% a year ago) but down 51% QoQ. The gap between standalone (-7% YoY revenue) and consolidated (+163% YoY revenue) growth is a consolidation effect and should not be read as core-business momentum.
Q1 FY-2027 vs prior quarters
No year-ago quarter on record — YoY cells may be blank.
Margins are the weak spot in the print: consolidated EBITDA (PBT + finance cost + depreciation) works out to roughly 17.9% of revenue, versus 24.3% for standalone alone, and well short of management's guided 30-33% blended EBITDA margin. The dilution traces to the newly consolidated units, which run a ~6.1% net margin on their ₹57.07 Cr of revenue against Anlon's own ~15.5% standalone NPM. Consolidated PAT is also split with non-controlling interests (₹1.62 Cr of the ₹8.28 Cr) since Apiqo and Bizotic aren't fully owned yet; today's board approval of a share-swap to convert both into wholly-owned subsidiaries would remove that NCI drag on owners' PAT once completed.
The stock went into the print at ₹14.31, down 10% over the past month of trading.
What the summary numbers don't show
Board today approved a share-swap to convert Apiqo (32.52%) and Bizotic (43.33%) stakes into 100% ownership via preferential equity issue, removing future NCI drag
Management provides very optimistic guidance, targeting FY26 consolidated revenue of INR 190-200 crores and a conservative INR 370-380 crores for FY27, projecting an approximate 30% revenue CAGR over the next three years with a long-term potential of INR 650-700 crores by FY28. This growth is driven by acquisitions (Ap
— This quarter: missed
Against management's own guidance, FY26 consolidated revenue of ₹172.22 Cr came in below the ₹190-200 Cr targeted on the February 2026 concall — a miss. FY27 guidance calls for ₹370-380 Cr; Q1's ₹87.56 Cr annualizes to roughly ₹350 Cr, trailing even the low end by ~5-6%, extending that shortfall pattern, though management's thesis leans on the Apiqo/Bizotic ramp and a planned ₹100-120 Cr greenfield capex to back-load growth later in the year. No sell-side coverage or Q1 FY27 preview turned up in a search, so street positioning is unknown, and management issued no separate press commentary beyond the board-outcome filing.
W1
Completion of the Apiqo (32.52%) / Bizotic (43.33%) share-swap into wholly-owned subsidiaries — watch preferential equity dilution and whether NCI drag on PAT (₹1.62 Cr this quarter) disappears
W2
FY27 revenue run-rate vs guided ₹370-380 Cr — Q1 annualizes to ~₹350 Cr, ~5-6% short of the low end; check if Q2 closes the gap
W3
Consolidated EBITDA margin trajectory — Q1 at ~17.9% is well below the guided 30-33% blended margin; watch whether the newly consolidated units (~6.1% net margin) scale up or keep diluting
Consolidated PAT ₹8.28 Cr splits ₹6.66 Cr to owners and ₹1.62 Cr to non-controlling interests (Apiqo 32.52%-held, Bizotic 43.33%-held, not yet wholly owned); board approved a share-swap today to make both 100% subsidiaries. No exceptional/one-off items disclosed either period. Source figures in Lakhs, converted to Crore (÷100).
Strong revenue beat, EBITDA miss; margin recovery critical
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Missed EBITDA margin guidance by ~13 ppts; maintained revenue guidance but reduced EBITDA margin forecast from 30–33% to 25–27%.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Anlon delivered strong top-line growth (₹87.6 Cr, +163% YoY) but crushed EBITDA margin guidance (17.8% vs 30–33% prior), citing raw material inflation (methanol ₹22→₹58) and Remember India integration costs. Management claims Q2–Q3 recovery via price hikes, but Q1 'domino effect' logic—where cost increases offset selling price gains—suggests margin recovery is uncertain. Long-term 30% CAGR and ₹700 Cr FY28 target remain credible if new 1200 MT capacity executes on schedule, but near-term margin credibility is dented.
₹87.6 Cr
Revenue · +null% YoY₹8.3 Cr
Reported PAT · +null% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
EBITDA margin normalized; sustainable 25–30% by Q2–Q3
OVERSTATEDQ1 EBITDA margin ~17.8%; assumes price pass-through materializes
Raw material price increases 2–3× reflected in cost, pass-through underway
MISSMethanol ₹22→₹58; pass-through claimed but Q1 margin still collapsed
FY27 revenue 350–400 Cr guidance maintained
METGuidance range same, but acquisition-heavy; standalone Anlon ₹32 Cr in Q1
Capacity utilization 65–70%; peak revenue potential 350–400 Cr
OVERSTATEDOnly ₹87.6 Cr Q1 from ₹1400–1600 MT installed capacity suggests soft underlying demand
Earnings quality
What changed since the last call
EBITDA margin guidance cut
DowngradeFY27 EBITDA margin revised from 30–33% (prior calls) to 25–27% due to raw material inflation (methanol up 164%) and Remember India integration drag.
Revenue guidance maintained nominally
NeutralFY27 revenue range 350–400 Cr unchanged from prior 370–380 Cr midpoint, but composition shifted: acquisitions now ₹57 Cr of ₹87.6 Cr consolidated, vs standalone Anlon soft at ₹32 Cr.
Remember India timing pushed out
DowngradeNot included in FY27 ₹350–400 Cr guidance; now expected to contribute from Q4 FY27 at earliest, not earlier quarters.
Capex increased and debt-financed
New₹130 Cr capex for 1200 MT new capacity at Anlon standalone (vs prior ₹100–120 Cr plan); ₹70 Cr debt at 8.5–8.6%, rest internal.
The Q&A
Analysts pressed hard. Deepak Poddar asked when margins normalize (Q3 answer); Vaibhav Mishra questioned continuous margin decline vs peers; Paras Chheda challenged oil price hedging and working capital impact. Management held but was defensive, conceding 'domino effect' (cost and price hikes offset in percentage terms) and acknowledging B2B pricing rigidity (10–15 customers, 130–135 day payment terms).
Raw material cost pass-through — Deepak Poddar
PartialPrices up 2–3×, not normalized; domino effect means Q2 margin similar to Q1; full normalization by Q3 expected.
Margin decline vs guidance — Vaibhav Mishra
AnsweredOld orders locked in at prior prices; new orders at higher selling price. Acquisition burden (Remember India depreciation ₹1.29 Cr). FY27 consolidated margin 25–27% expected.
Remember India revenue contribution — Vaibhav Mishra
DodgedNot included in ₹350–400 Cr FY27 guidance. WHO-PQ approval expected by year-end; revenue likely Q4 FY27 onward. Will give exact figure in Q2 call.
Capacity utilization and revenue potential — Deepak Poddar
AnsweredPeak level revenue potential 350–400 Cr at full utilization; that's the FY27 target at 65–70% usage.
FY28 growth drivers — Deepak Poddar
AnsweredNew 1200 MT capacity at standalone Anlon, commissioned Q1 FY28 at 50–60% utilization initially, drives incremental ₹300 Cr revenue.
Oil price volatility and margin vulnerability — Paras Chheda
Partial~40% of API cost is solvents (petroleum-linked). Once-in-a-decade event; can't pass through daily; B2B limits pricing frequency. Long-term contracts mean we absorb temporary shock.
Working capital and cash flow impact — Paras Chheda
PartialTightening payment terms with customers; switching away from slow payers. Expect positive operating cash flow by end of FY27 (best efforts).
33% margin feasibility — Ashish Parikh
Answered33% not possible now. Industrial/fine chemicals business has lower margins. Operating costs rising (headcount, professionals). Expect 25–28% consolidated long-term.
Standalone Anlon revenue decline — Viraj Shah
PartialProduct mix timing; long production cycles (30–45 days or 40+ days) mean Q1 start → Q2 revenue recognition. H1 will show true picture.
Subsidiary expansion plans — Anshul Sharma
AnsweredBiologics (peptides, biosimilars) separate from pharma for regulatory clarity. Medicare (surgical implants) part of pain ecosystem. Revenue expected FY28 Q4 (Biologics) and Q2 (Medicare).
CDMO molecule progress — Ashish Parikh
DodgedSame status as last call (May); process validations ongoing; expect updates post-Q3.
Guidance
FY27 revenue ₹350–400 Cr (maintained from prior calls)
HighComposition: Anlon ₹180 Cr, Apiqo ₹120–150 Cr, Bizotic ₹60 Cr, Remember India ₹0 (not included). Achievable if Q2–Q3 execute as planned.
FY28 revenue ~₹700 Cr
MediumAssumes new 1200 MT Anlon capacity by Q1 FY28 at 50–60% utilization; incremental ₹300 Cr. Contingent on regulatory approvals and execution risk.
FY27 EBITDA margin 25–27% (revised from 30–33% prior)
MediumAssumes raw material price stabilization, price pass-through to customers, and Remember India integration drag easing. Q1 at 17.8% is below range; recovery assumed Q2–Q3.
FY27 PAT margin 12–13%
MediumConservative per management; assumes no major delays in capex; interest cost on ₹70 Cr debt ~₹1.5 Cr/quarter.
FY28 EBITDA margin 25–28% (similar to FY27)
MediumMay improve slightly with formulation revenue from Remember India (expected >25%), but industrial chemicals drag persists.
FY27 capex ₹130 Cr for 1200 MT new capacity at standalone Anlon
HighFinanced: ₹70 Cr debt (8.5–8.6% rate), ₹60 Cr internal. Construction and statutory approvals lined up; Q1 FY28 commissioning target (with contingency buffer).
Risks the call surfaced
Raw material volatility
HighMethanol up 164% (₹22→₹58); ~40% of API cost from petroleum solvents. Pass-through to B2B customers faces resistance; Q1 margin miss ~1300 bps.
Customer concentration
HighB2B business with ~10–15 key customers; pricing limited by customer power; 130–135 day payables (vs 90-day terms) indicates payment friction.
Remember India execution
HighAcquired May 2026, 63.98% stake; in validation/upgrade phase; no Q1 revenue; NOT included in FY27 ₹350–400 Cr guidance. WHO-PQ approval critical path; management won't commit to Q2–Q3 revenue.
Capex execution and capacity ramp
High₹130 Cr capex for 1200 MT new capacity at standalone Anlon; Q1 FY28 commissioning target subject to statutory approvals. Initial 50–60% utilization assumed; full ₹700 Cr FY28 target depends on demand materialization.
Standalone Anlon stagnation
MediumStandalone Anlon revenue ₹32 Cr in Q1, flat vs ₹33 Cr Q1 FY26. Already at peak 400 MT capacity; organic growth nil until new facility. FY27 revenue ₹180 Cr (annualized) is only 1% above FY26 ~178 Cr implied.
Management
Score 6/10. Moderately candid on challenges (margin miss, geopolitical pressures) but selective on timelines (Remember India revenue 'too early to comment'). Deflected some analyst pushback with 'once-in-a-lifetime' claims. Not fully transparent on Remember India ramp assumptions. Mixed track record. Prior calls guided 30–33% EBITDA margins; delivered 17.8% (43% miss). Revenue guidance maintained but acquisitions mask organic flatness. Capex projects on schedule (claims), but no track record on new facility execution.
1 · Q2 FY27
Price increases on new orders take hold; gross margin recovery begins
2 · Q3 FY27
Raw material costs stabilize; EBITDA margin guidance (25–27%) expected to crystallize
3 · Q4 FY27
Remember India commercial production starts; first revenue contribution
Long-term 30% CAGR and ₹700 Cr FY28 target remain credible if new 1200 MT capacity executes on schedule, but near-term margin credibility is dented.